Original article title

A. Author1, B. Author2, C. Author3 etc.

1 First author’s affiliation

2 Second author’s affiliation

3 Third author’s affiliation

**Abstract** Authors are kindly asked to insert their abstract here. The abstract should not exceed 250 words and should be structured as follows: **Introduction, Objective, Methods, Results, Conclusions.**

*Keywords: please provide 4-6 keywords,* We recommend using MeSH keywords <http://www.nlm.nih.gov/mesh/MBrowser.html>

**Correspondence to:**

Name Surname

Institute

Address

E-mail

Phone/Fax

# **Introduction**

This document is a template for Microsoft *Word*. Please type over sections of the template or cut and paste from another document. Please limit the text of your article to maximum of 3000 words and 50 references. Submission of a manuscript is held to imply that it has not previously been published or under revision by another journal.

State the purpose of the article and justify the study in the introductive section. Do not review the subject extensively and give only pertinent references. References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text by Arabic numerals in parenthesis (1). If you cite authors’ name please do it as follows: Brown (1) if one author, Brown & Jones (2) if two authors and Brown *et al.* (1) if more than two authors.

**Methods**

Authors are kindly required to describe study group selection (inclusion and/or exclusion criteria) and give details about randomization. Statistical analysis methods should be described in detail so that a knowledgeable reader could verify reported results. A p-value or confidence interval should be cited in the abstract and in the text for any statistically significant finding reported. Outcome variables should generally be given as point estimates, with 95% confidence intervals rather than standard deviations or standard errors. The type of statistical test employed, as well as the type of statistical software utilized—version, manufacturer, manufacturer’s location— must be identified for any analysis.

**Results**

Present results in logical sequence in the text, tables, and figures. The text should not reproduce the information given as tables or figures. When describing main findings please give specific reference to tables (Table II) and figures (Figure 2).

**Discussion**

Summarize main findings in an initial paragraph without reproducing in detail the information previously presented. Afterwards, place your study in context, referring to other relevant work. In the end, discuss the limitations of your study / methods and present the importance of your study as well as its implication for future research.

*Acknowledgements*

Acknowledge only people who have made substantive contributions to the study. Sources of support should be mentioned in this section.

*Conflict of interest*

Authors are responsible for recognizing and disclosing financial and/or other conflicts of interest that might bias their work. If there are no conflicts of interest, the authors should state, "The authors declare that there are no conflicts of interest."

**References**

References should be numbered consecutively in the order in which they are first mentioned in the text. Identify references in text by Arabic numerals in parenthesis.

Citation examples (Vancouver reference style):

**Journal article with author(s)**

* *less than 6 authors*

1. Nicoll R, Howard JM, Henein MY. A Review of the Effect of Diet on Cardiovascular Calcification. Int J Mol Sci. 2015;16(4):8861-83.

* *more than 6 authors*

1. Di Leo A, Curigliano G, Diéras V, Malorni L, Sotiriou C, Swanton C, et al. New approaches for improving outcomes in breast cancer in Europe. The Breast 2015;34(1):1-10.

**Journal article: No author**

1. 21st century heart solution may have a sting in the tail. BMJ. 2002;325(7537):184.

**Journal article: Organization as author**

1. Diabetes Prevention Program Research Group. Hypertension, insulin, and proinsulin in participants with impaired glucose tolerance. Hypertension. 2002;40(5):679-86.

**Supplement**

1. Geraud G, Spierings EL, Keywood C. Tolerability and safety of frovatriptan with short- and long-term use for treatment of migraine and in comparison with sumatriptan. Headache. 2002;42 Suppl 2:S93-9.

**Journal article online (.html from publisher’s Web site)**

1. Terrie YC. Treatment and management of dermatitis. Pharm Times [journal on the Internet]. 2013 Apr 18 [cited 2013 Aug 23]; Available from: http://www.pharmacytimes.com/publications/issue/2013/April2013/Treatment-and-Management-of-Dermatitis

**Journal article from an online journal database/aggregator**

1. Jones RW, McCrone P, Guilhaume C. Cost effectiveness of memantine in Alzheimer’s disease. Drugs Aging [serial on the Internet]. 2004 [cited 2005 Aug 23];21(9):607-20. Available from: EBSCOhost Research Databases/Academic Search Premier http://www.wilkes.edu/library/articles.asp

**Epub ahead of print**

1. McKeage K. Tobramycin inhalation powder: a review of its use in the treatment of chronic pseudomonas aeruginosa infection in patients with cystic fibrosis. Drugs [journal on the Internet]. 2013 Nov 6 [cited 2013 Nov 7]. Available from: http://link.springer.com/article/10.1007%2Fs40265-013-0141-0 [Epub ahead of print]

**Books**

* *Personal author(s)*

1. Murray PR, Rosenthal KS, Kobayashi GS, Pfaller MA. Medical microbiology. 4th ed. St. Louis: Mosby; 2002.

* *Editor(s), compiler(s) as author*

1. Gilstrap LC 3rd, Cunningham FG, VanDorsten JP, editors. Operative obstetrics. 2nd ed. New York: McGraw-Hill; 2002.

* *Organization(s) as author*

1. Royal Adelaide Hospital; University of Adelaide, Department of Clinical Nursing. Compendium of nursing research and practice development, 1999–2000. Adelaide (Australia): Adelaide University; 2001.

* *Chapter in a book*

1. Meltzer PS, Kallioniemi A, Trent JM. Chromosome alterations in human solid tumors. In: Vogelstein B, Kinzler KW, editors. The genetic basis of human cancer. New York: McGraw-Hill; 2002, p. 93-113.

**Web page with author**

1. Atherton, J. Behaviour modification [Internet]. 2010 [cited 2010 Apr 10]. Available from:

http://www.learningandteaching.info/learning/behaviour\_mod.htm.

**Web page – no author**

The family impact of Attention Deficit Hyperactivity Disorder (ADHD) [Internet] 2009 Nov 1 [cited 2010 Apr 8]. Available from: http://www.virtualmedicalcentre.com.au/healthandlifestyle.asp?sid=192&title=The-Family-Impact-of-Attention-Deficit-Hyperactivity-Disorder-%28ADHD%29&page=2.

**Tables**

Tables are to be numbered consecutively with roman numerals and indicated in text (Table II). Each table should be provided as a separate word file named accordingly (Table II.doc). When preparing tables, if you are using a table grid, use only one grid for each individual table and not a grid for each row. If no grid is used, use tabs, not spaces, to align columns. All tables should be created in a Microsoft Word document, do not use picture tools to create tables. Use additional pages when a table does not fit onto one page. Use the metric system when reporting measurements. Footnotes to tables are indicated by superscripted letters a, b, c, etc.

**Figures**

Tables are to be numbered consecutively with Arabic numerals and indicated in text (Figure 2). Each figure should be provided as a separate file (TIFF format, 300 dpi or higher resolution).

Maximum width for tables and figures: 8.2 cm for single column elements and 16.4 cm for whole page width elements.

Please provide descriptive table and figure titles after the references as follows:

**Table II. Search terms used in the electronic database searches.**

**Figure 2. Individualized therapy for cancer patients.**